 a. Study Overview: Once a patient with idiopathic MN and proteinuria 5g24h is identified and meets other entry criteria, heshe will receive a minimum of 4 months of non-immunosuppressive therapy aimed at maximizing Ang II blockade run-in phase. The target blood pressure 130 mmHg systolic BP 75 of the readings; but not 100 mmHg systolic is chosen based on recent recommendations by the JNC VII.38 1 The first step will be the administration of an ARB. This is chosen because ARBs are as effective as ACEIs in blocking the AT1 mediated adverse effects of Ang II, while being better tolerated, with minimal cough or angioedema, and less hyperkalemia. Because this part of the study aims to maximize Ang II blockade, ARB dose will continue to be increased every 2 weeks until the maximum toleratedFDA approved dose is achieved or until intolerable side effects occur e.g. development of postural hypotension, light headed, hyperkalemia, etc. 2 Once ARB dose has been maximize and there are no observable side-effects, andor blood pressure is not at target, a long acting ACEi will be added. ACEi dose will be increased every 2 weeks aiming to achieve maximum tolerated or maximum approved dosage. For patients whose blood pressure control is not at target additional medication will be added in the following order: 3 a loop diuretic, 4 a cardioselective β-blocker, 5 a non-dihydropyridine calcium channel blocker CCB, and 6 clonidine. The selection of these drugs adheres to the recommendation of the JNC VII.38 The choice of a non-dihydropyridine CCB was made because of concerns that dihydropyridine-type CCB may obscure the anti-proteinuric effects of the above therapy. In order to further ensure that any potential adverse effect is minimized we have limited CCB to be used as a fifth agent, and to be used only when the combination of ARBACEi, diuretic, and β-blocker have failed to reduce BP to target level. Concomitant Treatment: 1. At the start of the run-inconservative phase of the study, and as part of the standard of care for patients with NS and severe hyperlipidemia, patients will be started on atorvastatin 10 mg a day or its equivalent and if tolerated no evidence of persistent elevation of liver transaminase 3x upper limit of normal, muscle pain, high CK, or rhabdomyolysis the dose can be increased according to the recently published KDOQI-dyslipidemia guidelines.39 The dose should not be increased above the maximum of 40 mgday. The rationale for not using a higher statin dose is because of the risk of developing proteinuria with the use of statins at high doses. Patients will remain at the highest tolerated dose for the entire duration of the study. Serum lipids will be measured at baseline and every 3 months thereafter. 2. High sodium intake e.g. 200 mm NaCld or 4.6 g sodiumd can significantly impair the beneficial effects of Ang II blockade.40 Therefore patients will be instructed to go on a low salt diet 2-3gday. 3. Patients will receive dietary counseling at enrollment regarding a dietary protein target intake of 0.8 gkg ideal body weightday of high quality protein and will be encouraged to maintain the same diet throughout the duration of the study. 